Nelotanserin

Nelotanserin is an experimental drug candidate that was developed by Arena Pharmaceuticals for the treatment of Lewy body dementia, Parkinson's disease psychosis, and REM sleep behavior disorder. It is a selective 5-HT2A receptor antagonist.

History[edit | edit source]

Nelotanserin was originally developed by Arena Pharmaceuticals, a biopharmaceutical company based in the United States. The drug was designed to target the 5-HT2A receptor, a subtype of the serotonin receptor that is implicated in a variety of neurological and psychiatric disorders.

Clinical trials[edit | edit source]

In 2015, Arena Pharmaceuticals initiated a Phase 2 clinical trial of nelotanserin for the treatment of Lewy body dementia and Parkinson's disease psychosis. The trial was designed to evaluate the safety and efficacy of the drug in reducing hallucinations and other psychotic symptoms associated with these disorders.

In 2017, the company announced positive results from the trial, with nelotanserin demonstrating a significant reduction in psychotic symptoms compared to placebo. However, the drug did not meet its secondary endpoints, which included measures of sleep quality and cognitive function.

In 2018, Arena Pharmaceuticals initiated a Phase 2 clinical trial of nelotanserin for the treatment of REM sleep behavior disorder. The trial is currently ongoing.

Mechanism of action[edit | edit source]

Nelotanserin works by selectively blocking the 5-HT2A receptor. This receptor is involved in the regulation of mood, cognition, and sleep, and its overactivity is thought to contribute to the hallucinations and other psychotic symptoms seen in Lewy body dementia and Parkinson's disease psychosis.

See also[edit | edit source]

Nelotanserin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.